ZIVO Bioscience, Inc. (ZIVO)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

ZIVO Bioscience, Inc. (ZIVO) is down 57.6% since the beginning of the year. At $4 per share, ZIVO is trading 81.2% below its 52-week high of $20. Investors who bought $1,000 worth of ZIVO shares 5 years ago would now be looking at an investment worth $139.

ZIVO Bioscience, Inc. (ZIVO) has returned -57.59% so far this year and -74.05% over the past 12 months. Looking at the last ten years, ZIVO has achieved an annualized return of 26.00%, outperforming the S&P 500 Index benchmark, which averaged 13.88% per year.

Based on dividend-adjusted daily data since Sep 24, 2012, ZIVO's average daily return is +1.27%, while the average monthly return is +22.69%. At this rate, an investment would double in approximately 0.3 years.

Historically, 40% of months were positive and 60% were negative. The best month was May 2021 with a return of +3,026.9%, while the worst month was Nov 2023 at -74.4%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 10 months.

On a daily basis, ZIVO closed higher 35% of trading days. The best single day was May 28, 2021 with a return of +3,391.7%, while the worst single day was Nov 27, 2023 at -39.1%.

ZIVO Bioscience, Inc. has an annualized alpha of 2188.23%, beta of 0.40, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since September 24, 2012.

• This stock captured 178.47% of S&P 500 Index gains and 176.40% of its losses - amplifying both gains and losses, but participating more in upside than downside.
• Beta of 0.40 may look defensive, but with R2 of 0.00 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

ZIVO ranks 22 for risk / return — below 22% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the ZIVO Bioscience, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the ZIVO Bioscience, Inc. was 98.52%, occurring on Nov 28, 2023. The portfolio has not yet recovered.

The current ZIVO Bioscience, Inc. drawdown is 88.72%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of ZIVO Bioscience, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how ZIVO Bioscience, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.